Certara, Inc. Form 8-K Summary
Business context and reporting period
Certara, Inc. filed this Current Report on Form 8-K on June 14, 2021, reporting a board governance change effective June 15, 2021. The filing was made under Item 5.02, concerning the departure or appointment of directors and principal officers.
Board appointment and governance changes
- The Board increased its authorized size from eight to nine members pursuant to the amended and restated bylaws.
- Carol G. Gallagher, PharmD, was elected to the newly created Class III director position, effective June 15, 2021.
- Dr. Gallagher was appointed to the Compensation Committee and the Nominating and Corporate Governance Committee.
- Dr. Gallagher is a partner at New Enterprise Associates and has prior executive and board experience in the pharmaceutical and biotechnology industries.
- She will receive compensation under the company’s non-employee director compensation policy.
- Certara intends to enter into an indemnification agreement with Dr. Gallagher substantially similar to those provided to other directors.
Financial metrics and liquidity
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating or financial metrics.
Material changes, outlook, and risks
The filing reports a governance change only. It does not provide financial guidance, business outlook, management commentary on operations, new contingencies, or unusual financial items.
Important facts for investors to verify
- Dr. Gallagher’s effective appointment date: June 15, 2021.
- The Board’s new size of nine members and Dr. Gallagher’s classification as a Class III director.
- Her committee assignments and eligibility for non-employee director compensation.
- Whether and when the planned indemnification agreement was executed.
- Any subsequent filings describing changes to the Board, committee composition, or director compensation.